

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

DoHH2

RRID:CVCL_1179

Type: Cell Line

Proper Citation

IZSLER Cat# BS TCL 228, RRID:CVCL_1179

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1179

Proper Citation: IZSLER Cat# BS TCL 228, RRID:CVCL_1179

Description: Cell line DoHH2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:1849602](#), [PMID:7849311](#), [PMID:8057678](#), [PMID:8558920](#), [PMID:16960149](#), [PMID:17363600](#), [PMID:17495976](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:22460905](#), [PMID:23699601](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30165192](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Caution: A TP53 mutation is indicated as being at p.Ala138Pro (c.412G>C) in PubMed=17363600 but has not been confirmed by CCLE and Cosmic-CLP.,

Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: DoHH2

Synonyms: DOHH2, DoHH-2, DOHH-2

Cross References: CLO:CLO_0002805, CLO:CLO_0037050, EFO:EFO_0002167, CLDB:cl1086, CLDB:cl4974, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03472093, BioSample:SAMN10988489, cancercellines:CVCL_1179, Cell_Model_Passport:SIDM00981, ChEMBL-Cells:ChEMBL3308537, ChEMBL-Targets:ChEMBL2366181, Cosmic:906842, Cosmic:1086332, Cosmic:1629929, Cosmic:1995387, Cosmic:2297004, Cosmic:2437317, Cosmic-CLP:906842, DepMap:ACH-000056, DSMZ:ACC-47, DSMZCellDive:ACC-47, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS100ZVH, ENCODE:ENCBS652PBR, ENCODE:ENCBS662OGM, ENCODE:ENCBS898JGF, GDSC:906842, GEO:GSM115817, GEO:GSM179646, GEO:GSM201345, GEO:GSM886987, GEO:GSM888056, GEO:GSM1035327, GEO:GSM1374467, GEO:GSM1527310, GEO:GSM1527311, GEO:GSM1527312, GEO:GSM1527313, GEO:GSM1527314, GEO:GSM1527315, GEO:GSM1669740, IARC_TP53:21310, IARC_TP53:25029, ICLC:HTL99022, IGRhCellID:DOHH2, IZSLER:BS TCL 228, LiGeA:CCL_934, LINCS_LDP:LCL-1143, Lonza:666, PharmacDB:DOHH2_303_2019, PRIDE:PXD030304, Progenetix:CVCL_1179, PubChem_Cell_line:CVCL_1179, Wikidata:Q54831350

ID: CVCL_1179

Vendor: IZSLER

Catalog Number: BS TCL 228

Record Creation Time: 20220427T215821+0000

Record Last Update: 20260913T003017+0000

Ratings and Alerts

No rating or validation information has been found for DoHH2.

No alerts have been found for DoHH2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Wang B, et al. (2026) Axes of biological variation in diffuse large B cell lymphoma. Cancer cell.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. *Cell reports. Medicine*, 7(3), 102644.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. *Cancer cell*, 44(7), 1437.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. *iScience*, 28(6), 112584.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. *Blood cancer discovery*, 6(6), 580.

Lueg GA, et al. (2025) MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition. *Cell reports*, 44(9), 116180.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. *Frontiers in immunology*, 16, 1518787.

Dang D, et al. (2025) Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. *Cancer cell*, 43(6), 1159.

Reversat A, et al. (2025) Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. *European journal of immunology*, 55(12), e70101.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Diepstraten ST, et al. (2024) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. *Cancer cell*, 42(5), 850.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. *Cell reports. Medicine*, 5(2), 101421.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Donati G, et al. (2023) Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC-driven lymphoma. *EMBO molecular medicine*, 15(6), e16910.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Donati G, et al. (2022) Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. *Molecular oncology*, 16(5), 1132.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. *International journal of cancer*, 148(1), 150.

Gong C, et al. (2021) Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. *Molecular cell*, 81(19), 4059.